The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Candida Infection Testing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The candida infection testing market size has experienced robust growth in recent years. This market is set to expand from $16.72 billion in 2025 to $17.8 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.4%. Historically, the market’s expansion can be ascribed to several factors including the increasing incidence of fungal infections, the growing number of immunocompromised patient populations, the broadening of hospital diagnostic services, the adoption of culture-based fungal testing, and heightened awareness of antifungal resistance.
The candida infection testing market is projected for substantial growth in the upcoming years. By 2030, its valuation is anticipated to reach $22.56 billion, advancing at a compound annual growth rate (CAGR) of 6.1%. This anticipated expansion throughout the forecast period stems from several factors, including a heightened demand for swift fungal diagnostic tools, the growing acceptance of molecular and microbiome testing, the broadening availability of point-of-care fungal assessments, escalating investments in diagnostics for infectious diseases, and an intensified concentration on tailored antifungal treatments. Key developments during this period are characterized by the wider uptake of molecular methods for candida detection, an increase in the application of rapid NAAT-based testing, the progressing incorporation of microbiome analysis, the proliferation of hospital-based fungal diagnostic services, and a heightened emphasis on identifying fungal infections at an early stage.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19356&type=smp
What Drivers Are Influencing The Candida Infection Testing Market?
A rise in yeast infection cases is anticipated to fuel the expansion of the candida infection testing market. Yeast infections are fungal conditions stemming from excessive candida growth, typically impacting the mouth, genitals, and skin, frequently leading to symptoms like itching, redness, and discomfort. The main cause of yeast infections is an abundance of the candida fungus, often triggered by disruptions in the body’s natural bacterial balance, compromised immunity, or shifts in hormone levels. Candida infection testing is employed in cases of yeast infections to precisely identify candida overgrowth, thereby assisting medical professionals in confirming the infection and directing suitable treatment. For example, in May 2025, data from the UK Health Security Agency, a UK-based government public health body, indicated that bloodstream infections attributed to yeast in England increased by 4% in 2024 compared to 2023, rising from 2,170 to 2,247 reported cases, with the incidence rate climbing from 3.8 to 3.9 per 100,000 population during that identical timeframe. Consequently, the rising occurrence of yeast infections is set to stimulate the expansion of the candida infection testing market.
What Major Segment Divisions Exist Within The Candida Infection Testing Market?
The candida infection testing market covered in this report is segmented –
1) By Type: Invasive Candidiasis, Candidemia
2) By Test Type: Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test
3) By Application: Hospital, Laboratory
Subsegments:
1) By Invasive Candidiasis: Tissue Biopsy Testing, Urine Culture Testing, Blood Culture Testing
2) By Candidemia: Blood Tests, Serological Testing, Molecular Testing
How Are Trends Shaping The Direction Of The Candida Infection Testing Market?
Leading companies in the candida infection testing market are concentrating on developing technologically advanced solutions, such as completely automated PCR rapid tests for detecting candida, to enhance diagnostic precision and improve patient outcomes. A fully automated PCR rapid test for detecting candida refers to a sophisticated diagnostic tool that employs polymerase chain reaction (PCR) technology to quickly and accurately identify the presence of Candida species in clinical samples. For example, in May 2024, Bosch Healthcare Solutions GmbH, a Germany-based medical technology manufacturer, introduced a PCR test for candida auris detection on the Vivalytic platform, providing fully automated, rapid testing within an hour at the point of care. This advanced test enables prompt screenings and stands in contrast to traditional culture methods, which typically take one to three days in centralized labs, thus delaying diagnosis and treatment. Designed for clinical environments, the test is especially advantageous for high-risk patients, facilitating timely diagnosis and treatment to combat the serious health risks associated with C. auris infections.
Which Companies Are Leading Innovation In The Candida Infection Testing Market?
Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC
Read the full candida infection testing market report here:
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report
Which Regions Are Expected To Experience Rapid Expansion In The Candida Infection Testing Market?
North America was the largest region in the candida infection testing market in 2025. The regions covered in the candida infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Candida Infection Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19356&type=smp
Browse Through More Reports Similar to the Global Candida Infection Testing Market 2026, By The Business Research Company
Cancer Profiling Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report
Cancer Biomarker Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Cancer Diagnostics Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model